Major Lipids, Apolipoproteins, and Risk of Vascular Disease

被引:0
|
作者
Di Angelantonio, Emanuele
Sarwar, Nadeem
Perry, Philip
Kaptoge, Stephen
Ray, Kausik K.
Thompson, Alexander
Wood, Angela M.
Lewington, Sarah [2 ]
Sattar, Naveed [3 ]
Packard, Chris J. [3 ]
Collins, Rory [2 ]
Thompson, Simon G. [4 ]
Danesh, John [1 ]
机构
[1] Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Emerging Risk Factors Collaborat Coordinating Ctr, Cambridge CB1 8RN, England
[2] Univ Oxford, Oxford, England
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] MRC, Biostat Unit, Cambridge CB2 2BW, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 302卷 / 18期
基金
英国医学研究理事会;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; NONFASTING TRIGLYCERIDES; CARDIOVASCULAR-DISEASE; HDL CHOLESTEROL; ASSOCIATION; CORONARY; STROKE; PARTICIPANTS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified. Objective To assess major lipids and apolipoproteins in vascular risk. Design, Setting, and Participants Individual records were supplied on 302 430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes. Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. Results The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C. Conclusion Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. JAMA. 2009; 302(18): 1993-2000
引用
收藏
页码:1993 / 2000
页数:8
相关论文
共 50 条
  • [41] Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis
    Richardson, Tom G.
    Sanderson, Eleanor
    Palmer, Tom M.
    Ala-Korpela, Mika
    Ference, Brian A.
    Smith, George Davey
    Holmes, Michael V.
    PLOS MEDICINE, 2020, 17 (03)
  • [42] Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
    Rhainds, David
    Brodeur, Mathieu R.
    Tardif, Jean-Claude
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 244 - 256
  • [43] Blood Lipids, Lipoproteins, and Apolipoproteins With Risk of Coronary Heart Disease: A Prospective Study Among Multi-Racial Populations
    Deng, Kui
    Pan, Xiong-Fei
    Voehler, Markus W.
    Cai, Hui
    Cai, Qiuyin
    Shu, Xiao-Ou
    Gupta, Deepak K.
    Lipworth, Loren
    Zheng, Wei
    Yu, Danxia
    CIRCULATION, 2024, 149
  • [44] The association of circulating lipoprotein lipids and apolipoproteins with risk of endometriosis: a Mendelian randomization study
    He, Xiwen
    Xie, Shengyu
    Liu, Yi
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1186) : 578 - 583
  • [45] The role of lipids in transplant vascular disease
    McDonald, PC
    Kenyon, JA
    McManus, BM
    LABORATORY INVESTIGATION, 1998, 78 (10) : 1187 - 1201
  • [46] Lipids and Vascular Disease: A Framingham Perspective
    Wilson, Peter W. F.
    GLOBAL HEART, 2013, 8 (01) : 25 - 33
  • [47] ROUTINE EVALUATION OF SERUM-LIPIDS AND APOLIPOPROTEINS IN CHRONIC LIVER-DISEASE
    SCHLIENGER, JL
    DOFFOEL, M
    CHABRIER, G
    LAIDOUDI, A
    ABY, MA
    DIABETES & METABOLISM, 1981, 7 (03): : 204 - 204
  • [48] REFERENCE RANGES OF LIPIDS AND APOLIPOPROTEINS IN PREGNANCY
    PIECHOTA, W
    STASZEWSKI, A
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1992, 45 (01) : 27 - 35
  • [49] PLASMA-LIPIDS AND APOLIPOPROTEINS IN END-STAGE LIVER-DISEASE
    LONTIE, JF
    DUBOIS, DY
    MALMENDIER, CL
    MATHE, D
    ADAM, R
    GIGOU, M
    BISMUTH, H
    CLINICA CHIMICA ACTA, 1990, 195 (1-2) : 93 - 96
  • [50] Plasma Lipids, Apolipoproteins, and Subsequent Cognitive Decline in Men with Coronary Heart Disease
    Lutski, Miri
    Weinstein, Galit
    Goldbourt, Uri
    Tanne, David
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (03) : 827 - 837